Gufic Biosciences Limited has announced the opening of a special window for shareholders to re-lodge transfer deeds and dematerialize physical shares, following regulatory guidelines issued by the Securities and Exchange Board of India (SEBI).

Special Window Details

The pharmaceutical company has established this facility pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. The special window will remain operational from February 05, 2026 to February 04, 2027, providing shareholders with a one-year timeframe to complete their transactions.

Eligibility Criteria

The facility is designed for lodgement of physical securities transfer and dematerialization for shares that were sold or purchased prior to April 01, 2019. This includes cases where transfer requests were previously submitted but were rejected, returned, or not processed due to deficiencies in documents or processes.

Shareholders must meet specific eligibility requirements as outlined in the SEBI circular:

Processing Requirements

Only requests accompanied by original certificates along with transfer deeds and relevant supporting documents will be considered under this special window. The securities transferred through this process will be mandatorily credited to the transferee in dematerialized mode only.

Key restrictions include:

• Securities will remain under lock-in for one year from the date of registration of transfer
• No transfer, lien-marking, or pledging allowed during the lock-in period
• Original security certificates must be available for processing

Contact Information

For queries regarding the re-lodgement process, shareholders can contact the company's Registrar and Transfer Agent, MUFG Intime India Private Limited (formerly Link Intime India Private Limited), located at C-101, Embassy 247 Park, L.B.S. Marg, Vikhroli (West), Mumbai - 400083. Alternatively, shareholders may reach out to Gufic Biosciences' corporate office at SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400057.

The company has urged all eligible shareholders to take advantage of this special window, which has been introduced specifically for the benefit of investors holding physical shares.

Gufic Biosciences Limited has submitted its quarterly compliance certificate to the stock exchanges under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory certificate with both BSE and NSE on April 07, 2026.

Regulatory Compliance Filing

The certificate was submitted pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Ami Shah signed the filing on behalf of Gufic Biosciences Limited.

Registrar Confirmation

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. Ashok Shetty, Sr. Vice President-Corporate Registry, signed the confirmation on April 06, 2026.

The registrar confirmed that securities received from depository participants for dematerialisation during Q4 FY26 were processed according to prescribed timelines and regulatory requirements.

Quarter Activity Summary

A notable aspect of this filing is that no dematerialisation requests were received from shareholders during the quarter ended March 31, 2026. The registrar specifically noted this in their confirmation certificate.

Corporate Information

Gufic Biosciences Limited operates from its corporate office at SM House, Sahakar Road, Vile Parle (East), Mumbai, with its registered office located in Andheri (East), Mumbai. The company maintains manufacturing facilities across multiple states including Gujarat, Madhya Pradesh, and Karnataka.

This routine compliance filing demonstrates the company's adherence to SEBI regulations governing depositories and participant operations, ensuring transparency in share transfer and dematerialisation processes.